Zydus Lifesciences Limited has informed the Exchange regarding a press release dated July 24, 2025, titled "Zydus receives tentative approval from USFDA for Ibrutinib tablets 140 mg, 280 mg, and 420 mg".
Press Release Jul 24 2025
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it received tentative approval from the USFDA for Ibrutinib tablets in various strengths. Ibrutinib is a medication used for treating specific types of blood cancers. The tablets will be manufactured at Zydus's facility in Ahmedabad, and the product had significant annual sales in the United States. This approval adds to Zydus's growing portfolio, with a total of approvals and applications filed since the start of their filing process.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release 17-07-2025 NewspaperpublicationAGMnotice17072025
- Press Release Jul 16 2025
- Press Release Jul 15 2025
- Press Release Jun 18 2025
- Press Release Jun 11 2025
Later from Zydus Lifesciences
- Press Release Jul 29 2025
- Press Release Aug 07 2025
- Press Release Aug 08 2025
- Press Release Aug 11 2025
- Press Release Aug 12 2025
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences